Exapto

Paris, FR · 1 known investors

Exapto develops engineered biocomponents — novel patented metabolic pathways and enzymes — for industrial biomanufacturing, aimed at improving existing bioproductions and enabling access to chemicals that were previously unreachable from renewable resources. The company combines synthetic biology and AI in its R&D stack to produce key chemicals for the biomanufacturing industry.